Physician profile
Jason Gross
NPI 1609862846
$5,860.09
in general payments reported to CMS, 2019-2025
21 companies · $1,132 in 2025
The $1,132 reported for 2025 was more than what 80% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $737 · 2020: $772 · 2021: $531 · 2022: $413 · 2023: $1,628 · 2024: $647 · 2025: $1,132.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,407.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,407.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $1,781.68 | 2019-2025 | Clareon, Centurion, Argos |
| Johnson & Johnson Surgical Vision, INC. | $1,246.90 | 2019-2025 | Veritas Vision System, Tecnis Simplicity, Tecnis Iol |
| Carl Zeiss Meditec USA, INC. | $605.46 | 2023-2025 | Iolmaster 700, Quatera 700, Callisto Eye |
| Rxsight INC | $389.12 | 2023-2024 | Rxsight Injector Handpiece, Rxsight Injector Cartridge, Rxsight Light Delivery Device (Ldd) |
| Tarsus Pharmaceuticals, INC. | $319.60 | 2024-2025 | Xdemvy |
| Ivantis, INC | $220.42 | 2019-2021 | |
| Abbvie INC. | $197.58 | 2022-2025 | |
| Sun Pharmaceutical Industries INC. | $185.82 | 2019-2025 | |
| Bausch & Lomb Americas INC. | $160.99 | 2024-2025 | Miebo, Xiidra, Vyzulta |
| Glaukos Corporation | $146.68 | 2023 | Istent Infinite Trabecular Micro-Bypass System Model Is3, Is3-Istent Infinitetrabecular Micro-Bypass System Model Is3 |
| Heidelberg Engineering, INC. | $93.70 | 2025 | Spectralis |
| Aerie Pharmaceuticals, INC. | $91.49 | 2019-2020 | |
| Thea Pharma INC. | $90.36 | 2023-2025 | Iyuzeh |
| Allergan, INC. | $79.79 | 2020-2022 | |
| Kala Pharmaceuticals, INC. | $72.76 | 2019-2021 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotissue Holdings INC. | $48.09 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $43.62 | 2019 | |
| Amgen INC. | $25.15 | 2025 | Tepezza |
| Oyster Point Pharma, INC. | $23.89 | 2023 | Tyrvaya |
| Dompe US, INC. | $22.98 | 2025 | Oxervate |
| Astellas Pharma US INC | $14.01 | 2024 | Izervay |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jason Gross listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.